| Trial ID: | L3196 |
| Source ID: | NCT01536665
|
| Associated Drug: |
Liraglutide
|
| Title: |
The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: liraglutide|DRUG: placebo
|
| Outcome Measures: |
Primary: Geometric mean glucagon concentration during hypoglycaemia (nadir glucose (target 2.5 mmol/L) ), At week 4 | Secondary: Geometric mean glucagon concentration at plasma glucose levels other than nadir, At week 4|Geometric mean concentrations of adrenaline and noradrenaline at nadir, At week 4|Time from termination of insulin infusion at nadir to reach plasma glucose 4.0, At week 4
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
45
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2012-02
|
| Completion Date: |
2012-08
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-08
|
| Locations: |
Novo Nordisk Investigational Site, Graz, 8036, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT01536665
|
